127 related articles for article (PubMed ID: 35995724)
1. Individualized dosimetry in Ru-106 ophthalmic brachytherapy based on MRI-derived ocular anatomical parameters.
Liakopoulos DA; Perisinakis K; Solomou G; Kouvidakis A; Drakonaki EE; Bontzos G; Papadaki E; Detorakis ET
Brachytherapy; 2022; 21(6):904-911. PubMed ID: 35995724
[TBL] [Abstract][Full Text] [Related]
2. Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions.
Tien CJ; Astrahan MA; Kim JM; Materin M; Chen Z; Nath R; Liu W
Brachytherapy; 2017; 16(5):1057-1064. PubMed ID: 28778599
[TBL] [Abstract][Full Text] [Related]
3. MRI and dual-energy CT fusion anatomic imaging in Ru-106 ophthalmic brachytherapy.
Detorakis ET; Perisinakis K; Drakonaki E; Liakopoulos D; Tzedakis A; Papadaki E; Tsilimbaris MK
Brachytherapy; 2021; 20(4):828-834. PubMed ID: 33785279
[TBL] [Abstract][Full Text] [Related]
4. A Monte Carlo dose calculation system for ophthalmic brachytherapy based on a realistic eye model.
Miras Del Río H; Ortiz Lora A; Bertolet Reina A; Terrón León JA
Med Phys; 2021 Aug; 48(8):4542-4559. PubMed ID: 34250607
[TBL] [Abstract][Full Text] [Related]
5. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.
Morrison H; Menon G; Larocque MP; Jans HS; Weis E; Sloboda RS
Med Phys; 2016 Aug; 43(8):4891. PubMed ID: 27487906
[TBL] [Abstract][Full Text] [Related]
6. Independent dosimetric assessment of the model EP917 episcleral brachytherapy plaque.
Aryal P; Molloy JA; Rivard MJ
Med Phys; 2014 Sep; 41(9):092102. PubMed ID: 25186402
[TBL] [Abstract][Full Text] [Related]
7. Multidimensional dosimetry of ¹⁰⁶Ru eye plaques using EBT3 films and its impact on treatment planning.
Heilemann G; Nesvacil N; Blaickner M; Kostiukhina N; Georg D
Med Phys; 2015 Oct; 42(10):5798-808. PubMed ID: 26429254
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
[TBL] [Abstract][Full Text] [Related]
9. MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy.
Zoberi JE; Garcia-Ramirez J; Hedrick S; Rodriguez V; Bertelsman CG; Mackey S; Hu Y; Gach HM; Rao PK; Grigsby PW
Brachytherapy; 2018; 17(1):31-39. PubMed ID: 28818442
[TBL] [Abstract][Full Text] [Related]
10. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
[TBL] [Abstract][Full Text] [Related]
11. Investigation of gold nanoparticle effects in brachytherapy by an electron emitter ophthalmic plaque.
Hashemi S; Aghamiri MR; Kahani M; Jaberi R
Int J Nanomedicine; 2019; 14():4157-4165. PubMed ID: 31239674
[No Abstract] [Full Text] [Related]
12. Quantifying the dosimetric influences of radiation coverage and brachytherapy implant placement uncertainty on eye plaque size selection.
Gagne NL; Rivard MJ
Brachytherapy; 2013; 12(5):508-20. PubMed ID: 23466357
[TBL] [Abstract][Full Text] [Related]
13. Personalized treatment planning in eye brachytherapy for ocular melanoma: Dosimetric analysis on ophthalmic structure at risk.
Itta F; Liuzzi R; Farella A; Porri G; Pacelli R; Conson M; Oliviero C; Buonanno F; Breve MA; Cennamo G; Clemente S; Cella L
Phys Med; 2020 Aug; 76():285-293. PubMed ID: 32738776
[TBL] [Abstract][Full Text] [Related]
14. Hydrogen nanobubbles: A novel approach toward radio-sensitization agents.
Hashemi S; Aghamiri SM; Siavashpour Z; Kahani M; Zaidi H; Jaberi R
Med Phys; 2023 Oct; 50(10):6589-6599. PubMed ID: 37278345
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
16. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.
Barker CA; Francis JH; Cohen GN; Marr BP; Wolden SL; McCormick B; Abramson DH
Brachytherapy; 2014; 13(6):584-90. PubMed ID: 24880583
[TBL] [Abstract][Full Text] [Related]
17. Treatment plan optimization and robustness of
Heilemann G; Fetty L; Dulovits M; Blaickner M; Nesvacil N; Georg D; Dunavoelgyi R
Radiother Oncol; 2017 Apr; 123(1):119-124. PubMed ID: 28185660
[TBL] [Abstract][Full Text] [Related]
18. Cerenkov Luminescence Imaging for Accurate Placement of Radioactive Plaques in Episcleral Brachytherapy of Intraocular Tumors.
Axelsson J; Krohn J
Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7362-8. PubMed ID: 26562170
[TBL] [Abstract][Full Text] [Related]
19. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators.
Flühs D; Anastassiou G; Wening J; Sauerwein W; Bornfeld N
Med Phys; 2004 Jun; 31(6):1481-8. PubMed ID: 15259651
[TBL] [Abstract][Full Text] [Related]
20. Dose characteristics of Au-198 eye brachytherapy applicator: A Monte Carlo study.
Kamrani S; Aghamiri SMR; Hashemi S
Appl Radiat Isot; 2021 Oct; 176():109866. PubMed ID: 34293507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
